FindTrial
Sign In

The efficacy and safety of nasal sustained release administration of dextrometadiazine in nasal endoscopic surgery

The efficacy and safety of nasal sustained release administration of dextrometadiazine in nasal endoscopic surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025692
Enrollment
Unknown
Registered
2019-09-05
Start date
2018-11-20
Completion date
Unknown
Last updated
2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasal septum deviation, sinusitis, rhinitis, nasal bone fracture

Interventions

DEX-1:1 ug /kg dexmedetomidine (10ml)
DEX-2:2 ug /kg dexmedetomidine
DEX-3:4 ug /kg dexmedetomidine
Placebo:Physiological saline

Sponsors

the First Affiliated Hospital of Shantou University Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing bilateral nasal endoscopic surgery under general anesthesia; 2. ASA grades I-II; 3. Aged 18-65 years; 4. BMI 18 kg/m2 to 35 kg/m2.

Exclusion criteria

Exclusion criteria: 1. History of drug dependence, chronic pain and mental illness; 2. Users of preoperative painkillers and sedatives; 3. Allergic to dexmedetomidine, or allergic to proposed general anesthesia; 4. Alcoholics and chronic insomniacs; 5. Illiterate, hearing impaired and uncooperative; 6. Refuse to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
Pain score;Sleep quality score;—

Secondary

MeasureTime frame
Satisfaction score;Total hospitalization cost;—

Countries

China

Contacts

Public ContactYuting Wang

the First Affiliated Hospital of Shantou University Medical College

wangyuting_0210@163.com+86 13729266433

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 23, 2026